Lung cancer is the most frequently life‐threatening disease and the prominent cause of cancer‐related mortality among human beings worldwide, where poor early diagnosis and expensive detection costs are considered as significant reasons. Here, we try to tackle this issue by proposing a novel label‐free and low‐cost strategy for rapid detection and distinction of lung cancer cells relying on plasmonic toroidal metasurfaces at terahertz frequencies. Three disjoint regions are displayed in identifiable intensity‐frequency diagram, which could directly help doctors determine the type of lung cancer cells for clinical treatment. The metasurface is generated by two mirrored gold split ring resonators with subwavelength sizes. When placing analytes on the metasurface, apparent shifts of both the resonance frequency and the resonance depth can be observed in the terahertz transmission spectra. The theoretical sensitivity of the biosensor over the reflective index reaches as high as 485.3 GHz/RIU. Moreover, the proposed metasurface shows high angular stability for oblique incident angle from 0 to 30°, where the maximum resonance frequency shift is less than 0.66% and the maximum transmittance variation keeps below 1.33%. To experimentally verify the sensing strategy, three types of non‐small cell lung cancer cells (Calu‐1, A427, and 95D) are cultured with different concentrations and their terahertz transmission spectra are measured with the proposed metasurface biosensor. The two‐dimensional fingerprint diagram considering both the frequency and transmittance variations of the toroidal resonance dip is obtained, where the curves for different cells are completely separated with each other. This implies that we can directly distinguish the type of the analyte cells and its concentration by only single spectral measurement. We envisage that the proposed strategy has potential for clinical diagnosis and significantly expands the capabilities of plasmonic metamaterials in biological detection.

Background and objective: Esophageal cancer (EC) is the seventh most prevalent cancer globally and the sixth leading cause of cancer-related mortality. This study aimed to provide an updated stratified assessment of rates in EC incidence, mortality, and disability-adjusted life-years (DALYs) from 1990 to 2021 by sex, age, and Socio-demographic Index (SDI) at global, regional, and national levels, as well as to project the future trends of EC both globally and regionally. Methods: Data about age-standardized rates (ASRs) of incidence (ASIR), mortality (ASDR), probability of death (ASPoD) and DALYs (ASDALYRs) of EC were obtained from the 2021 Global Burden of Disease (GBD) study. Estimated annual percentage changes (EAPCs) and average annual percentage changes (AAPC) were calculated over certain periods to describe the temporal trends of EC burdens. The analyses were disaggregated by sexes, GBD super-regions and regions, nations/territories, age-groups, and SDI quintiles. A Bayesian age-period-cohort (BAPC) model was constructed to project the global and regional EC ASRs in 2022–2035. Results: Despite global reductions in EC ASRs, with ASIR, ASDR, and ASDALYR in 2021 of 6.65 [5.88, 7.45] (95% uncertainty interval), 6.25 [5.53, 7.00], and 148.56 [131.71, 166.82], decreasing by 24.9%, 30.7%, and 36.9% in 1990–2021, respectively, the absolute burden numbers were increased from 1990 to 2021, probably because of population growth and aging. Global newly diagnosed cases, deaths, and DALYs of EC increased to 576,529 [509,492, 645,648], 356,263 [319,363, 390,154], and 12,999,265 [11,522,861, 14,605,268] in 2021, by 62.53%, 51.18%, and 33.28% compared to records in 1990. The geographical pattern of EC was consistent: locations with the highest EC incidence and mortality rates were predominantly located in the Asian Esophageal Cancer Belt and African Esophageal Cancer Corridor, with East Asia, Southern Sub-Saharan Africa, and Eastern Sub-Saharan Africa as the GBD regions with the heaviest EC burdens, and Malawi, Eswatini, Mongolia, Zambia, and Zimbabwe with the most EC ASRs in 2021. However, owing to the population size, China, India, the United States, Japan, and Brazil had the heaviest absolute EC burdens. More pronounced alleviations of ASRs were observed in locations with high SDI levels, indicated by their lower AAPC values compared to those of low-SDI locations, while Sub-Saharan Africa regions had increasing EC ASRs, especially in Chad (114.76% in ASDR, for example), Sao Tome and Principe (97.93%), Togo (92.53%), Northern Mariana Islands (84.32%), Liberia (82.33%), etc. Smoking remained the leading contributor to EC ASDALYR globally and across most GBD super-regions in 2021. The EC burden is significantly heavier for males, with incidence and mortality in males in 2021 being 2.89 and 2.88 times higher, respectively, than in females. Across all age groups, EC posed an increasingly significant threat to men aged > 75 years. From 2022 to 2035, the ASR projections show only modest decrease in both global and regional EC burdens, and the absolute burden numbers are expected to increase globally and in nearly all GBD super-regions. Conclusion: EC burden remains significant, with disparities across sexes, age groups, and regions. Region-specific and age-targeted measures are crucial to addressing these inequalities, especially in light of increasing EC burdens in older men and in African regions. Efforts should be taken in finding more solid attributions to risk factors for EC burdens and to better identify high-risk populations to inform targeted prevention and screening, and ultimately reduce the EC burden in an efficient and cost-effective way. Graphical

A 5-T MRI system provided similar image quality compared with 7 T but higher image quality than 3-T images when evaluating intracranial vessels and associated small branches. Background Three-dimensional (3D) time-of-flight (TOF) MR angiography (MRA) at 7 T has been reported to have high image quality for visualizing small perforating vessels. However, B1 inhomogeneity ...